首个治疗2型糖尿病的GIP和GLP-1双重受体激动剂:替尔泊肽

First GIP and GLP-1 dual receptor agonist for treatment of type 2 diabetes:tirzepatide

替尔泊肽能够选择性地结合并激活葡萄糖依赖性促胰岛素多肽(GIP)和胰高血糖素样肽1(GLP-1)受体。2022年5月替尔泊肽被美国食品和药物管理局批准上市,在饮食控制和运动的基础上,用于改善2型糖尿病成年患者的血糖控制。临床研究表明,替尔泊肽可有效改善血糖控制并减轻患者体重,其常见的不良反应包括恶心、腹泻、食欲下降等。

Tirzepatide can selectively bind to and activate both the glucose-dependent insulinotropic peptide(GIP)and glucagon-like peptide 1(GLP-1)receptors.Tirzepatide was approved by the U.S.Food and Drug Administration in May 2022 as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.Clinical trials have shown that tirzepatide is effective in improving blood sugar control and weight loss in patients.Common adverse reactions of tirzepatide include nausea,diarrhea,decreased appetite,etc.